Capricor Therapeutics (NASDAQ:CAPR) Trading Down 6% – Here’s Why

Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) fell 6% during trading on Tuesday . The stock traded as low as $11.90 and last traded at $12.11. 317,967 shares traded hands during trading, a decline of 77% from the average session volume of 1,357,926 shares. The stock had previously closed at $12.88.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $77.00 price target on shares of Capricor Therapeutics in a research note on Monday. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $34.50.

Capricor Therapeutics Trading Down 6.9 %

The stock has a market cap of $545.19 million, a P/E ratio of -11.31 and a beta of 4.10. The company has a 50 day simple moving average of $14.14 and a 200 day simple moving average of $14.46.

Hedge Funds Weigh In On Capricor Therapeutics

Large investors have recently modified their holdings of the business. Summit Investment Advisors Inc. boosted its position in Capricor Therapeutics by 54.1% during the fourth quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company’s stock valued at $53,000 after purchasing an additional 1,345 shares during the last quarter. Russell Investments Group Ltd. raised its stake in shares of Capricor Therapeutics by 172.8% during the 4th quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company’s stock worth $64,000 after purchasing an additional 2,947 shares in the last quarter. Virtus ETF Advisers LLC bought a new stake in shares of Capricor Therapeutics during the 4th quarter worth approximately $68,000. AlphaQuest LLC acquired a new stake in shares of Capricor Therapeutics in the 4th quarter valued at approximately $78,000. Finally, New York State Common Retirement Fund grew its stake in shares of Capricor Therapeutics by 625.0% in the fourth quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 5,000 shares in the last quarter. 21.68% of the stock is currently owned by institutional investors and hedge funds.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.